Why These 5 Stocks Are in the Spotlight on Monday

2. ImmunoGen, Inc. (NASDAQ:IMGN) has declined by more than 23.2% as of 10:17 AM ET after the biotech company presented the final results for Mirvetuximab in the treatment of platinum-resistant ovarian cancer. The analysts have not considered the final results favorable. Kennen MacKay at RBC Capital Markets downgraded ImmunoGen, Inc. (NASDAQ:IMGN) from an Outperform to a Sector Perform rating and slashed the price target from $9 to $6. The analyst also lowered Mirvetuximab’s probability of success from 85% to 50%. ImmunoGen, Inc.  (NASDAQ:IMGN) was held by 31 hedge funds as of Q4 2021, with a combined value of $502.9 million.